Sara A. Hurvitz, MD, Discusses Outcomes With Sacituzumab Govitecan By Age for Metastatic Triple-Negative Breast Cancer
CancerNetwork® sat down with Sara A. Hurvitz, MD, at the 2021 ASCO Annual Meeting to talk about multidisciplinary care with geriatrician oncologists and the use of age-based analyses for diagnosis and following up of metastatic triple-negative breast cancer.
At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Sara A. Hurvitz, MD, from the University of California, Los Angeles Jonsson Comprehensive Cancer Center, about utilizing sacituzumab govitecan (Trodelvy) for the treatment of older patients with metastatic triple-negative breast cancer (mTNBC).
Sacituzumab govitecan was examined in the phase 3 ASCENT study (NCT02574455) in patients with relapsed/refractory TNBC with subgroup analyses performed to assess the impact of age. The study found that regardless of age (≥65 or <65 years), patients who had received 2 or more chemotherapies had a significant survival benefit with use of sacituzumab govitecan.
Transcript:
It’s quite important for us as clinical investigators to explore outcomes based on age. We do have an aging population and cancer is a disease that, at least in breast cancer, increases [with patients who are] increasing in age. It is really important for us to look at outcomes based on age. From a geriatrician standpoint, I think they would support this type of analysis because treatment decisions across the board—whether it’s in cardiology, pulmonology, oncology, or endocrinology—should be based on a patient’s performance status and ability to accept therapy rather than a numerical age. I’m reassured that these data show a similar efficacy outcome with the use of sacituzumab as well as a reasonable safety profile. The data will make us all more comfortable offering this therapy that’s associated with a survival benefit to patients, regardless of their age. I’m sure geriatric oncologists applaud this type of analysis.
Reference:
Kalinsky K, Oliveira M, Traina T, et al. Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of Sacituzumab govitecan (SG) in metastatic triple negative breast cancer (mTNBC). J Clin Oncol. 2021;39(suppl 15):1011. doi: 10.1200/JCO.2021.39.15_suppl.1011
Gedatolisib Combo With/Without Palbociclib May Be New SOC in PIK3CA Wild-Type Breast Cancer
December 21st 2025“VIKTORIA-1 is the first study to demonstrate a statistically significant and clinically meaningful improvement in PFS with PAM inhibition in patients with PIK3CA wild-type disease, all of whom received prior CDK4/6 inhibition,” said Barbara Pistilli, MD.
